UBS Group
CMRAW

UBS Group’s Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 CMRAW Stock Holding History

UBS Group’s Portfolio CMRAW Stock Details CMRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,219
Closed – – 11413
2022
Q3 		$0 Buy
6,219
+1,319
+27% +$130 ﹤0.01% 11291
2022
Q2 		$1K Buy
+4,900
New +$802 ﹤0.01% 10082

Other funds holding CMRAW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

UBS Group's CMRAW Position: Q4 2022 in Review

UBS Group sold out of Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 (CMRAW) in Q4 2022, closing a stake of 6,219 shares.

UBS Group first reported a position in CMRAW in Q2 2022 and held it in 2 quarters. The position peaked at $1K in Q2 2022. 14 funds tracked by Wall St. Rank hold CMRAW as of Q4 2022.

  • UBS Group reported no remaining Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 position as of Q4 2022 after selling out during the quarter.
  • UBS Group sold 6,219 Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 shares in Q4 2022.
  • UBS Group first reported a position in Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 in Q2 2022 and held it in 2 quarters.
  • UBS Group's Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 position peaked at $1K in Q2 2022.
  • 14 funds tracked by Wall St. Rank held Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.